NAMI
TVTX icon

Nomura Asset Management International’s Travere Therapeutics TVTX Stock Holding History

Nomura Asset Management International’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160M Sell
2,812,514
-457,999
-14% -$20.3M 0.24% 71
2026
Q1 		$97.2M Sell
3,270,513
-503,051
-13% -$15M 0.17% 147
2025
Q4 		$144M Buy
+3,773,564
New +$123M 0.22% 101

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Nomura Asset Management International's TVTX Position: Q2 2026 in Review

Nomura Asset Management International reduced its Travere Therapeutics (TVTX) stake by 14% in Q2 2026, selling an estimated $20.3M and leaving 2,812,514 shares worth $160M. The position accounts for 0.24% of the portfolio, ranked #71.

Nomura Asset Management International first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. 317 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Nomura Asset Management International held 2,812,514 shares of Travere Therapeutics worth $160M as of Q2 2026.
  • Nomura Asset Management International sold 457,999 Travere Therapeutics shares in Q2 2026, an estimated $20.3M.
  • Travere Therapeutics made up 0.24% of Nomura Asset Management International's portfolio in Q2 2026, its #71 holding.
  • Nomura Asset Management International first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 317 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Nomura Asset Management International's 13F filing for Q2 2026, filed 14 Aug 2026.